SCHEMBL4676364

SCHEMBL4676364

O=C(O)C(O)=CC(=O)c1csc(Cc2cccc(F)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.40
HCAR2 Q8TDS4 2/20 0.38
GPR52 Q9Y2T5 1/20 0.38
NR4A2 P43354 2/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
LTB4R Q15722 1/20 0.36
SLC1A1 P43005 2/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676359 1.00 DAO (0.40) DAOHCAR2GPR52NR4A2MAPK1
SCHEMBL4670645 0.87 DAO (0.49) DAOGPR52MAPK1RAB9AMEN1
SCHEMBL4670642 0.87 DAO (0.49) DAOGPR52MAPK1RAB9AMEN1
SCHEMBL4673684 0.86 KDM4E (0.38) DAONR4A2MAPK1RAB9ALMNA
SCHEMBL4673686 0.86 KDM4E (0.38) DAONR4A2MAPK1RAB9ALMNA
SCHEMBL4673126 0.79 HPGD (0.40) DAORAB9AMEN1KMT2ALMNA
SCHEMBL4673133 0.79 HPGD (0.40) DAORAB9AMEN1KMT2ALMNA
SCHEMBL4676593 0.79 MAPT (0.40) DAOHCAR2GPR52NR4A2MAPK1
SCHEMBL7826756 0.79 PTPN1 (0.51) DAOHCAR2NR4A2MAPK1RAB9A
SCHEMBL4670644 0.79 HCAR2 (0.39) HCAR2GPR52NR4A2MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 DAO 661/4885HCAR2 276/4885GPR52 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.